Medytox posts record Q1 revenue, driven by toxin exports and portfolio expansion

Medytox, a Korean biopharmaceutical company specializing in botulinum toxin therapies, said it achieved consolidated revenue of 64 billion won ($45.6 million) in the first quarter of 2025, marking a 17 percent increase from the same period last year. Operating profit and net income turned positive, reaching 5.5 billion won and 3.3 billion won, respectively, from an operating and net loss of 930 million won and 1.4 billion won in the first quarter of last year. 

The company’s first-quarter revenue marked an all-time high for the period, supported by balanced growth in both Korean and international markets. Sales in Korea rose 26 percent year-on-year, while overseas revenue climbed 12 percent. Notably, the South America region, led by Brazil, recorded a sharp 88 percent increase, solidifying its position as a major export destination.

Medytox’s botulinum toxin franchise, including flagship products Meditoxin, Innotox, and Coretox, was the primary growth driver.

The company also added a fourth product, Newlux, to its portfolio, helping to diversify its offerings. Korean toxin sales surged 79 percent year-on-year, with overseas sales increasing by 16 percent.

The company attributed part of its performance to the ramp-up of its third manufacturing plant in Osong, which began large-scale exports in the second half of 2024. With Newlux now entering global markets, Medytox expects revenue acceleration to continue throughout the year as more international approvals are secured.

“The strength of Medytox’s differentiated toxin portfolio, combined with brand recognition initiatives, has enabled us to achieve record first-quarter revenue,” a company official said. “We expect growth momentum to continue in the second quarter, with additional overseas approvals for Newlux and the launch of two new HA filler lines under the Neuramis brand.”

The year 2025 represents a pivotal year for Medytox in its evolution into a global player, and the company’s key priorities include securing regulatory approval for its proprietary fat-dissolving injectable in Korea, and preparing for the global launch of MT10109L, a next-generation liquid botulinum toxin formulation aimed at advanced markets, he added.